Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen Inc's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.

Amgen says Lumakras cuts risk of lung cancer progression by 34%

At 1-Year, Progression-Free Survival was 25% for LUMAKRAS Versus 10% for Docetaxel LUMAKRAS Met Key Secondary Endpoint of Objective Response Rate THOUSAND OAKS, Calif. , Sept. 11, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced detailed results from the global Phase 3 CodeBreaK 200 trial, which showed once-daily oral LUMAKRAS®/LUMYKRAS® (sotorasib) led to significantly superior progression-free survival (PFS; primary endpoint) and a significantly higher objective response rate (ORR; a key secondary endpoint) in patients with KRAS G12C-mutated non small cell lung cancer (NSCLC), compared with intravenous chemotherapy, docetaxel.

LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER

AbbVie

Biogen

Pfizer

Is now a good time to add these biotech stocks to your watchlist?

Best Stocks To Buy Now? 4 Biotech Stocks In Focus

Amgen's biosimilar drug is close to stealing away sales from AstraZeneca's rare disease drug called Soliris.

Could This Biosimilar Drug Candidate Be a Winner for Amgen?

VanEck Vectors Biotech ETF

Chemocentryx

Invesco Dow Jones Industrial Average Dividend ETF

iShares Nasdaq Biotechnology ETF

Mirati Therapeutics

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.

Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth

THOUSAND OAKS, Calif. , Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Morgan Stanley's 2022 Global Healthcare Conference at 9:10 a.m.

AMGEN ANNOUNCES WEBCAST OF 2022 MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

Amgen Inc. (NASDAQ:AMGN ) 2022 Wells Fargo Healthcare Conference September 8, 2022 9:45 AM ET Company Participants Peter Griffith - Chief Financial Officer David Reese - Executive Vice President of Research and Development Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Great, thank you very much for joining us today. Good morning.

Amgen Inc. (AMGN) Presents at 2022 Wells Fargo Healthcare Conference (Transcript)

SPROUT Data Show Otezla Resulted in Significant Improvements in Measures of Moderate to Severe Plaque Psoriasis at Week 16 Compared With Placebo in Children Ages 6-171 DISCREET 16-week Data Demonstrated Statistically Significant Improvements in Genital Psoriasis, Including Skin, Itch and Quality of Life, in Patients With Moderate to Severe Disease2 Adverse Events Were Consistent With Known Safety Profile of Otezla in Both Studies THOUSAND OAKS, Calif. , Sept. 8, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, at the 31st European Academy of Dermatology and Venereology (EADV) Congress, taking place in Milan, Italy, Sept.

AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)

THOUSAND OAKS, Calif. , Sept. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) at 1:30 p.m.

AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022

Amgen Inc. (NASDAQ:AMGN ) 2022 Citi Global Technology Conference Call September 7, 2022 8:50 AM ET Company Participants Peter Griffith - Chief Financial Officer David Reese - Executive Vice President of R&D Conference Call Participants Neena Bitritto-Garg - Citigroup Neena Bitritto-Garg All right. Well, good morning, everyone, and thank you for taking the time to join Citi's Annual Biopharma Conference.

Amgen Inc. (AMGN) 2022 Citi Global Technology Conference (Transcript)

Amgen stock (NASDAQ: AMGN) has seen an 8% rise this year, far better than the broader S&P500 index, which is down 18%.

What's Driving Amgen Stock Higher?

American Express

Caterpillar

Chevron

Johnson & Johnson

Coca-Cola

Walmart

Today I'm writing about Dow stocks to buy. Seasoned investors are realizing that many of the 30 members of the Dow Jones Industrial Average (DJIA) are now trading at low valuation levels and prices.

7 Dow Stocks With Superior Fundamentals

Cisco Systems

JPMorgan Chase & Co

Walgreens

Should investors be watching these dividend paying stocks this week?

Best Dividend Stocks To Invest In Right Now? 4 For Your List

THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Wells Fargo's 2022 Global Healthcare Conference at 9:45 a.m.

AMGEN ANNOUNCES WEBCAST OF 2022 WELLS FARGO HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , Sept. 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2022 Global Healthcare Conference at 8:50 a.m.

AMGEN ANNOUNCES WEBCAST OF 2022 CITI GLOBAL HEALTHCARE CONFERENCE

Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.

Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study

Amgen stock jumped Wednesday after outperforming expectations in a lung-cancer study. It brought rival Mirati along for the ride.

Why Amgen's Cancer Drug Results Gave This Small Cap A Big Boost

The company finds some protection against measures aimed to cut industry drug prices.

What This News Might Mean for Amgen

LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to be Presented at an Upcoming Medical Congress THOUSAND OAKS, Calif. , Aug. 30, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS® (sotorasib) met its primary endpoint of progression-free survival (PFS), demonstrating statistical significance and superiority over standard of care chemotherapy, intravenous docetaxel.

AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER

Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

New Positive Data From Phase 3 SPROUT Trial, Studying Otezla (apremilast) in Children Ages 6-17 With Moderate to Severe Plaque Psoriasis Positive Results From the Phase 3 DISCREET Study, Investigating Clinical Efficacy and Safety of Otezla in Patients With Moderate to Severe Genital Psoriasis New Rocatinlimab Phase 2 Analyses Highlight Emerging Clinical Profile in Moderate to Severe Atopic Dermatitis THOUSAND OAKS, Calif. , Aug. 30, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that clinical and real-world data from across its inflammation portfolio, including both established treatments and pipeline assets, will be presented at the 31st European Academy of Dermatology and Venereology (EADV), taking place in Milan, Italy, Sept.

AMGEN TO PRESENT NEW, POSITIVE CLINICAL AND REAL-WORLD DATA ACROSS INFLAMMATION PORTFOLIO AT EADV 2022

Bristol-Myers

CVS Health

Gilead Sciences

Eli Lilly

Merck

The stock market rally ran into the harsh reality last Friday that any interest rate pivot by the Federal Reserve may not come until 2024.

8 Safe ‘Strong Buy' Health Care Dividend Stocks to Buy as Summer Bear Market Rally Ends

Earlier Treatment With Repatha Resulted in a Lower Incidence of Major CV Events, Including CV Death 80% of Patients Achieved Guideline Directed LDL-C Levels of

NEW AMGEN DATA AT ESC 2022 SHOW LONG-TERM LDL-C LOWERING WITH REPATHA® (EVOLOCUMAB) WAS WELL-TOLERATED FOR MORE THAN 8 YEARS

Amgen is showing very low implied volatility compared to recent history. That could mean it's a good time to buy an option strangle.

Take Advantage Of Low Volatility In Amgen Stock With Options

Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.

News for Amgen Stock (AMGN)